ProVen VCT plc: Total voting rights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Apple’s first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
Tweet
Share
E-mailProVen VCT plc
Total Voting Rights
2 January 2025
In conformity with the Disclosure and Transparency Rule 5.6.1, ProVen VCT plc announces that the Company's capital and voting rights, as at 31 December 2024, are summarised as follows:
| Shares in issue | Voting rights per Share | Voting rights | |
| Ordinary shares of 10p each | 270,953,118 | 1 | 270,953,118 |
| Total voting rights | 270,953,118 | ||
The Company does not hold any shares in treasury.
The above takes account of any shares that have been recently bought back for cancellation, even if such transactions have not yet settled.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, ProVen VCT plc under the FCA's Disclosure and Transparency Rules.
Beringea LLP
Company Secretary
Telephone 020 7845 7820
- End
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
- ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
- Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
